Brief: AB Science Presents Phase 2B/3 Study Results For Masitinib
14/09/2020 06:48
Sept 14 (Reuters) - AB SCIENCE SA ABS.PA :
* AB SCIENCE PRESENTS PHASE 2B/3 STUDY RESULTS IN
PROGRESSIVE
MULTIPLE SCLEROSIS AT THE WORLD'S LARGEST MULTIPLE SCLEROSIS
RESEARCH CONFERENCE
* MASITINIB PROVIDES FIRST CLINICAL EVIDENCE THAT TARGETING
INNATE
IMMUNE SYSTEM IS AN EFFECTIVE STRATEGY FOR THE TREATMENT OF
PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
Source text for Eikon: ID:nGNE17JB5K
Further company coverage: ABS.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease